Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2020 after the close
Received EUA and initiated gammaCore Sapphire CV distribution process for certain known or suspected COVID-19 patients experiencing asthma exacerbations Generated sequential increase in revenue Further strengthened balance sheet and reduced quarterly cash burn Company to host conference call and
Reimbursement for gammaCore™ in England BASKING RIDGE, N.J. , Aug. 24, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Official Journal of the European Union (OJEU) has published a Voluntary ex-ante Transparency
BASKING RIDGE, N.J. , Aug. 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts 1 ,” by Wittbrodt,
BASKING RIDGE, N.J. , Sept. 11, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that management is scheduled to present at the HC Wainwright Virtual 22nd Annual Global Investment Conference , which is being held from
BASKING RIDGE, N.J. , Sept. 23, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger , chief executive officer, will participate in a fireside chat at the JMP Securities MedTech Bio Summit, which is being
Comprehensive telehealth platform to facilitate the efficient procurement of gammaCore Sapphire™ CV (non-invasive vagus nerve stimulator) by known or suspected COVID-19 patients BASKING RIDGE, N.J. , Sept. 24, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage
BASKING RIDGE, N.J. , Sept. 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Department of Veterans Affairs has agreed to sponsor a quadruple blind, randomized, sham-controlled clinical trial of non-invasive
ITP program providing reimbursement for gammaCore ™ extended to March. 31, 2021 with option for additional three years The potential contract value if the three-year extension option is exercised could be up to approximately £3.6 million (or approximately $4.6 million based on the current exchange
BASKING RIDGE, N.J., October 6, 2020 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, chief executive officer, will provide a corporate update at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually October